Compare YAAS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YAAS | KPRX |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 8.0M |
| IPO Year | N/A | N/A |
| Metric | YAAS | KPRX |
|---|---|---|
| Price | $1.26 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 38.1K | ★ 83.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $1.76 |
| 52 Week High | $7.00 | $4.18 |
| Indicator | YAAS | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 43.34 |
| Support Level | $1.23 | $2.01 |
| Resistance Level | $1.34 | $2.26 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 39.13 | 9.09 |
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.